Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will ...
Financing pushes Vancouver startup closer to clinical trials targeting diabetes, liver disease. Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to ...
Novo Nordisk and Aspect Biosystems have started a new phase in their ongoing partnership focused on curative cellular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results